• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Current treatments

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival.
Palumbo A et al. J Clin Oncol. 2014 Jan 21. [Epub ahead of print].

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
Merz M et al. Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.

Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Chim CS et al. Hematol Oncol. 2014 Jan 29. doi: 10.1002/hon.2131. [Epub ahead of print].

A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Bensinger WI et al. Bone Marrow Transplant. 2014 Jan 13. doi: 10.1038/bmt.2013.219. [Epub ahead of print].

A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Richardson PG et al. Blood. 2014 Jan 15. [Epub ahead of print].

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Richardson PG et al. Blood. 2014 Jan 13. [Epub ahead of print].

  • Guidelines
  • Patient Support and Information
  • Medical animations
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG